Anticancer effect of bisphosphonates: New insights from clinical trials and preclinical evidence

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 299-307

  Daniele, Gennaro ^a   Giordano, Pasqualina ^a   De Luca, Antonella ^a   Piccirillo, Maria Carmela ^a   Di Maio, Massimo ^a   Giudice, Antonia Del ^a   De Feo, Gianfranco ^a   Bryce, Jane ^a   Lamura, Luana ^a   Vecchione, Aldo ^a   Normanno, Nicola ^a   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

adjuvant therapy; bisphosphonates; breast cancer; clinical trials; preclinical studies

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETIDRONIC ACID; GERANYLTRANSFERASE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; NERIDRONIC ACID; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; TILUDRONIC ACID; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE DENSITY; BONE MARROW BIOPSY; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 79952162021     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.214     Document Type: Review

References (61)

1. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21(21), 4042-4057 (2003).
2. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19(3), 420-432 (2008).
3. Catterall JB, Cawston TE. Drugs in development: bisphosphonates and met alloproteinase inhibitors. Arthritis. Res. Ther. 5(1), 12-24 (2003).
4. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2), 75-85 (1996).
5. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25(1), 97-106 (1999).
6. Lehenkari PP, Kellinsalmi M, Napankangas JP et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61(5), 1255-1262 (2002).
7. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82(8), 1459-1468 (2000).
8. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15(11), 2211-2221 (2000).
9. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57(18), 3890-3894 (1997).
10. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60(11), 2949-2954 (2000). Seminal evidence that bisphosphonates (BPs) impair invasion and bone metastases formation.
11. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells invitro. Tumour Biol. 27(2), 92-103 (2006).
12. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int. J. Cancer 113(3), 364-371 (2005).
13. Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol. Rep. 12(5), 1109-1114 (2004).
14. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cellsin vitro: evidence of synergistic interaction. Br. J. Cancer 102(6), 1010-1017 (2010).
15. Melisi D, Caputo R, Damiano V et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr. Relat. Cancer 12(4), 1051-1058 (2005).
16. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84(8), 1126-1134 (2001).
17. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin. Oncol. 28(2Suppl. 6), 35-44 (2001).
18. Michigami T, Hiraga T, Williams PJ et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res. Treat. 75(3), 249-258 (2002).
19. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61(11), 4418-4424 (2001).
20. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst. 99(4), 322-330 (2007).
21. Ottewell PD, Deux B, Monkkonen H et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin. Cancer Res. 14(14), 4658-4666 (2008).
22. Hiraga T, Williams PJ, Ueda A, TamuraD, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/lucmouse breast cancer model. Clin. Cancer Res. 10(13), 4559-4567 (2004).
23. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl Cancer Inst. 100(16), 1167-1178 (2008).
24. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J. Biol. Chem. 278(44), 43603-43614 (2003).
25. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302(3), 1055-1061 (2002).
26. Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9(8), 2893-2897 (2003).
27. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur. J. Cancer 46(7), 1211-1222 (2010). Well-written, timely and very interesting review on recent findings regarding BPs and other new agents targeting the bone incancer.
28. Thompson K, Roelofs AJ, Jauhiainen M, Monkkonen H, Monkkonen J, Rogers MJ. Activation of gd T cells by bisphosphonates. Adv. Exp. Med. Biol. 658, 11-20 (2010).
29. Malkovska V, Cigel FK, Armstrong N, Storer BE, Hong R. Antilymphoma activityof human γδ T-cells in mice withsevere combined immune deficiency. Cancer Res. 52(20), 5610-5616 (1992).
30. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2), 384-392 (2000).
31. Caccamo N, Meraviglia S, Cicero G et al. Aminobisphosphonates as new weapons for γδ T cell-based immunotherapy of cancer. Curr. Med. Chem. 15(12), 1147-1153 (2008).
32. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V γ 9V δ 2 γδ-T cells in vitro and in SCID mice in vivo. J. Immunol. 173(11), 6767-6776 (2004).
33. Kunzmann V, Bauer E, Wilhelm M. γ/δT-cell stimulation by pamidronate. N. Engl. J. Med. 340(9), 737-738 (1999).
34. Dieli F, Gebbia N, Poccia F et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102(6), 2310-2311 (2003).
35. Dieli F, Vermijlen D, Fulfaro F et al. Targeting human {γ}δ} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67(15), 7450-7457 (2007). Evidence of new a mechanism for BPs activity in cancer patients.
36. Wilhelm M, Kunzmann V, Eckstein S et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1), 200-206 (2003).
37. Elomaa I, Blomqvist C, Porkka L et al. Clodronate for osteolytic metastases due to breast cancer. Biomed. Pharmacother. 42(2), 111-116 (1988).
38. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skelet al metastases in women with breast cancer. Bone 19(6), 663-667 (1996).
39. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. 246(1), 67-74 (1999).
40. Mardiak J, Bohunicky L, Chovanec J, SalekT, Koza I. Adjuvant clodronate therapy in patients with locally advanced breast cancer - long term resultsof a double blind randomized trial. Slovak Clodronate Collaborative Group. Neoplasma 47(3), 177-180 (2000).
41. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br. J. Cancer 96(12), 1796-1801 (2007).
42. Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer113(1), 193-201 (2008).
43. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologic 12(9), 1035-1043 (2007).
44. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360(7), 679-691 (2009).
45. Gnant M, Mlineritsch B, Stoeger H et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J. Clin. Oncol. 28(15s) (2010). Update of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12 trial.
46. Bedard PL, Body JJ, Piccart-Gebhart MJ. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. J. Clin. Oncol. 27(25), 4043-4046 (2009).
47. Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronicacid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 112(5), 1001-1010 (2008).
48. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: anopen label, randomised, Phase 2 trial. Lancet Oncol. 11(5), 421-428 (2010).
49. Rack B, Jueckstock J, Genss E-M et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Breast Cancer Res. Treat. 106(Suppl.), S40 (2007).
50. Solomayer E, Gebauer G, Hirnle P et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at: San Anonio Breast Cancer Symposium 2008. San Antonio, TX, USA, 10-14 December 2008.
51. Coleman RE, Winter MC, Cameron D et al. The effects of adding zoledronic acidto neoadjuvant chemotherapy on tumour response: exploratory evidence fordirect anti-tumour activity in breast cancer. Br. J. Cancer 102(7), 1099-1105 (2010). The Breast International Group (BIG) 1-04/Does Adjuvant Zoledronic acid Reduce Recurrence in Patients with High Risk Localized Breast Cancer? (AZURE) trial report.
52. Powles T, McCroskey E, Paterson A. Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin. Cancer Res. 12(20 Pt 2), 6301s-6304s (2006).
53. Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339(6), 357-363 (1998). First clinical evidence of the potential anti-tumor effect of BPs.
54. Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol. 19(12), 2007-2011 (2008).
55. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skelet al metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 19(1), 10-17 (2001).
56. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 43(7), 650-656 (2004).
57. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer 102(5), 799-802 (2010). Seminal paper on the relationship between BP use for bone health and breast cancer incidence in a population-based case-control study.
58. Chlebowski RT, Chen Z, Cauley JA et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J. Clin. Oncol. 28(22), 3582-3590 (2010). Relevant paper on the chemopreventive role of BPs. A significative number of subjects are involved. Along with [57] and[59], provides a rationale for conducting prospective trials evaluating this hypothesis.
59. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol. 28(22), 3577-3581 (2010).
60. Coleman R, Bundred N, De Boer R et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9-13 December 2009 (Abstract 4082).
61. ClinicalTrials.gov http://clinicaltrials.gov